Sugi Predict

Sugi Predict / Compounds / SCHEMBL2106140

SCHEMBL2106140

SCHEMBL2106140

NC(=O)CN1CCSCC1

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.56
▸ ALDH1A1 P00352 7/20 0.41
▸ TSHR P16473 2/20 0.40
▸ POLB P06746 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ LMNA P02545 1/20 0.36
▸ ARG1 P05089 1/20 0.36
▸ ARG2 P78540 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ GAA P10253 1/20 0.34
▸ RAD52 P43351 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1007971 0.86 — —
SCHEMBL5307853 0.82 — —
SCHEMBL458012 0.82 KDM4E (0.68) KDM4EALDH1A1TSHRPOLBPKM
SCHEMBL3624681 0.82 KDM4E (0.68) KDM4EALDH1A1TSHRPOLBPKM
SCHEMBL2821117 0.82 KDM4E (0.68) KDM4EALDH1A1TSHRPOLBPKM
SCHEMBL4768884 0.78 HSD17B10 (0.52) KDM4EALDH1A1PKMLMNAARG1
SCHEMBL6445312 0.78 ALDH1A1 (0.39) KDM4EALDH1A1PKMLMNAARG1
SCHEMBL2911096 0.77 L3MBTL1 (0.63) KDM4EALDH1A1POLBLMNAARG1
SCHEMBL168399 0.77 — —
SCHEMBL1259867 0.77 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2964635-A1 ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2016-01-13 — — EP claimed
WO-2014135495-A1 ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2014-09-12 — — WO claimed
JP-2002512230-A — — 2002-04-23 — — JP claimed
EP-1071668-A1 5-AMINOINDENO(1,2-C)PYRAZOL-4-ONES AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS Du Pont Pharmaceuticals Company (US) 2001-01-31 — — EP claimed
WO-1999054308-A1 5-AMINOINDENO(1,2-C)PYRAZOL-4-ONES AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS DU PONT PHARMACEUTICALS COMPANY (US) 1999-10-28 — — WO claimed
CN-119930602-A Pyrimidine ring-containing 2, 5-disubstituted thiadiazole compound, and preparation method and application thereof 山东第二医科大学 2025-05-06 — — CN disclosed
CN-115160193-B Naphthalene sulfonamide micromolecule compound and application thereof 中国人民解放军海军军医大学 2023-09-15 — — CN disclosed
US-11746091-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2023-09-05 — — US disclosed
US-20230033510-A1 Compounds and Methods for Treatment of Visceral Pain ARENA PHARMACEUTICALS, INC. 2023-02-02 — — US disclosed
CN-115160193-A Naphthalene sulfonamide micromolecule compound and application thereof 中国人民解放军海军军医大学 2022-10-11 — — CN disclosed
US-11214548-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2022-01-04 — — US disclosed
US-20210188781-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2021-06-24 — — US disclosed
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2012-08-23 — — US disclosed
EP-2470508-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2012-07-04 — — EP disclosed
US-8163740-B2 6-substituted benzoxazines HOFFMANN-LA ROCHE INC. (US) 2012-04-24 — — US disclosed
US-7820707-B2 Heterocyclic derivatives N.V. ORGANON (NL) 2010-10-26 — — US disclosed
US-20100063037-A1 6-SUBSTITUTED BENZOXAZINES F. HOFFMANN-LA ROCHE AG (CH) 2010-03-11 — — US disclosed
EP-2041124-A1 PYRAZOLEALKANAMIDE SUBSTITUTED THIOPHENES AS AMPA POTENTIATORS N.V. Organon (NL) 2009-04-01 — — EP disclosed
US-20080255086-A1 Heterocyclic Derivatives N.V. ORGANON (NL) 2008-10-16 — — US disclosed
WO-2008003452-A1 PYRAZOLEALKANAMIDE SUBSTITUTED THIOPHENES AS AMPA POTENTIATORS N.V. ORGANON (NL) 2008-01-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 KDM4E 3533/4885ALDH1A1 3623/4885TSHR 1295/4885
US-11746091-B2 Cannabinoid receptor modulators CNR1, CNR2, TRPV1 KDM4E 3533/4885ALDH1A1 3623/4885TSHR 1295/4885
US-20080255086-A1 Heterocyclic Derivatives GRIN2C, GRIN3A, GRIN1 KDM4E 2605/4885ALDH1A1 453/4885TSHR 535/4885
US-20100063037-A1 6-SUBSTITUTED BENZOXAZINES HTR5A, NPY5R, GABRA5 KDM4E 944/4885ALDH1A1 1883/4885TSHR 670/4885
US-11214548-B2 Cannabinoid receptor modulators CNR1, CNR2, TRPV1 KDM4E 3533/4885ALDH1A1 3623/4885TSHR 1295/4885
US-20230033510-A1 Compounds and Methods for Treatment of Visceral Pain VIP, FABP2, FABP6 KDM4E 2319/4885ALDH1A1 603/4885TSHR 4484/4885
US-20210188781-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 KDM4E 3533/4885ALDH1A1 3623/4885TSHR 1295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.